Trial · NCT01726816
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
NCT01726816, Phase 2, Completed, Korea Otsuka Pharmaceutical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy. Trials, record NCT01726816. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01726816
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
- NCT number
- NCT01726816
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 126 participants, actual
- Lead sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Conditions
- Diabetic Nephropathy
- Interventions
- Probucol 250mg/day, Probucol 500mg/day, Placebo
- First posted
- 2012-11-15
- Last updated
- 2017-05-03
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | A/C ratio | 16 week | The change in the A/C ratio from baseline to the end of treatment(16 week) \[Time Frame: baseline to 16 weeks\] |
| Secondary | Serum creatinine | 16 week | The change in the Serum creatinine from baseline to the end of treatment. |
| Secondary | eGFR | 16 week | The change in the eGFR from baseline to the end of treatment(16 week) |
| Secondary | cystatin C | 16 week | The change in the cystatin C from baseline to the end of treatment(16 week) |
| Secondary | urine albumin | 16 week | The change in the urine albumin from baseline to the end of treatment(16 week) |
| Secondary | P/C ratio | 16 week | The change in the P/C ratio from baseline to the end of treatment(16 week) |
| Other | Total Cholesterol | 16 week | The change in the Total cholesterol from baseline to the end of treatment(16 week) |
| Other | Triglyceride | 16 week | The change in the Triglyceride from baseline to the end of treatment(16 week) |
| Other | LDL-C | 16 week | The change in the LDL-C from baseline to the end of treatment(16 week) |
| Other | HDL-C | 16 week | The change in the HDL-C from baseline to the end of treatment(16 week) |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 27493100 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01726816
GET https://conductscience.org/api/trials/v1/NCT01726816/registered